Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: petruzzo m. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M. De Mercanti SF, et al. Among authors: petruzzo m. J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6. J Neurol Sci. 2021. PMID: 33770708
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R, Moccia M, Palladino R, Signoriello E, Carotenuto A, Maniscalco GT, Saccà F, Bonavita S, Russo CV, Iodice R, Petruzzo M, Sinisi L, De Angelis M, Lavorgna L, De Rosa A, Romano F, Orlando V, Ronga B, Florio C, Lus G, Brescia Morra V. Lanzillo R, et al. Among authors: petruzzo m. Mult Scler Relat Disord. 2020 Feb;38:101871. doi: 10.1016/j.msard.2019.101871. Epub 2019 Nov 25. Mult Scler Relat Disord. 2020. PMID: 31786463
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, Di Filippo M, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia AL, Petruzzo M, De Angelis M, Brescia Morra V, Solaro C, Gasperini C, Cocco E, Moccia M, Lanzillo R; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Buonomo AR, et al. Among authors: petruzzo m. J Neurol. 2022 Jun;269(6):3301-3307. doi: 10.1007/s00415-022-11009-x. Epub 2022 Feb 14. J Neurol. 2022. PMID: 35165767 Free PMC article.
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M, Lavorgna L, Trojsi F, Moccia M, Fratta M, Capasso N, Dubbioso R, Petracca M, Spiezia AL, Gallo A, Petruzzo M, De Angelis M, Bonavita S, Lus G, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: petruzzo m. J Clin Med. 2022 Apr 7;11(8):2081. doi: 10.3390/jcm11082081. J Clin Med. 2022. PMID: 35456175 Free PMC article.
145 results